|
Clinical Convergence: Patient and Provider Perspectives in IBD
Gastroenterology
Curriculum:
Clinical Convergence: Patient and Provider Perspectives in IBD Enduring
Clinical Convergence: Patient and Provider Perspectives in IBD Enduring
Credits:
2.25 AMA PRA Category 1 Credit(s) ™
2.25 AMA PRA Category 1 Credit(s) ™
Launch Date:
January 12, 2017
January 12, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Gastroenterologists and gastroenterology nurse practitioners (NPs) and physician assistants (PAs)
Relevant Terms:
IBD
Sunanda Kane, MD, MSPH
Sunanda Kane, MD, MSPH (National Chair)
Professor of Medicine
Mayo Clinic Rochester
Rochester, MN
Bio
Sunanda Kane MD, MSPH, FACG, FACP, AGAF, earned her doctor of medicine degree at Rush Medical College in Chicago, Illinois. She completed a residency at Rush-Presbyterian-St. Luke’s Medical Center. She then completed her fellowship at the University of Chicago. Dr. Kane is board certified in internal medicine and gastroenterology.Dr. Kane currently works as a Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where she also serves as a Consultant to the Department of Medicine’s Division of Gastroenterology and Hepatology, as well as a Staff Member on the GI Epidemiology/Outcomes Research Unit and a Faculty Member for Mayo Clinic Quality Academy. She has a busy clinical practice and sees patients with inflammatory bowel disease, conducting research in the areas of new therapies, gender specific issues, and medication adherence. In addition to her personal research and practice, Dr. Kane travels to give lectures at national symposia and other medical facilities in the United States and across the world.
Dr. Kane has contributed over 120 papers of original research, 50 reviews, and 25 book chapters to the medical literature. She co-edited a pocket guide to the management of IBD for practitioners, and wrote a book for patients on IBD self-management. She served as the first female Associate Editor for Alimentary Pharmacology and Therapeutics and continues to serve editorial roles for Inflammatory Bowel Diseases, Gastroenterology & Hepatology, and the Journal of Crohn’s and Colitis.
Sasha Taleban, MD
Sasha Taleban, MD (Regional Chair)
Assistant Professor
Director, Inflammatory Bowel Disease (IBD) Program
University of Arizona
Tucson, AZ
Bio
Sasha Taleban, MD, earned his doctor of medicine degree at the University of Washington School of Medicine, and went on to Rhode Island Hospital/Brown for gastroenterology fellowship and completed an Advanced IBD Fellowship at Cedars-Sinai Medical Center. He is board certified in internal medicine and gastroenterology.
Dr. Taleban is the Director of the Inflammatory Bowel Disease (IBD) Program at the University of Arizona, where he also works as an Assistant Professor.
Dr. Taleban’s research interests include aging and quality improvement in IBD and general gastroenterology. He has multiple publications in various journals covering a variety of topics, and currently serves as a journal reviewer for American Journal of Gastroenterology, Inflammatory Bowel Disease Journal, Journal of Crohn’s and Colitis, and Digestive Diseases and Sciences, among others. Dr. Taleban has a series of national abstracts that have been published, and he has participated in numerous projects, seminars, and conferences.
Gary R. Lichtenstein, MD
Gary R. Lichtenstein, MD
Professor of Medicine
Director, IBD Center
University of Pennsylvania School of Medicine
Philadelphia, PA
Bio
Gary R. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center, in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School Of Medicine.Dr. Lichtenstein is Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease and has had a significant focus on the safety of current and future medical therapy. He has also focused his research on the natural history of disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn’s disease.
A Fellow of the American Gastroenterological Association, the American College of Physicians and the American College of Gastroenterology, Dr. Lichtenstein has been listed in “Best Doctors in America” (inflammatory bowel disease), and has served as Medical Secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level, including the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, and the American College of Gastroenterology. He is also a member of the Crohn’s and Colitis Foundation of America (CCFA) where he served at the national level as the chair of the membership committee of the Clinical Research Alliance, and on the national grants review committee and the national professional education committee. Dr. Lichtenstein is a longstanding member of the American College of Physicians and the American Medical Association.
Dr. Lichtenstein has received numerous awards, including the National Scientific Achievement Award from CCFA, the Louis A. Duhring Award, and the Christina and Marie Lindback award. In addition to having served on the Editorial Board of the journals Gastroenterology, American Journal of Gastroenterology, Inflammatory Bowel Diseases, World Journal of Gastroenterology, and Digestive Diseases and Sciences, Dr. Lichtenstein serves as a reviewer for The New England Journal of Medicine, Gastroenterology, The Lancet, among many others. He is the executive editor of a newly PubMed-indexed journal Gastroenterology and Hepatology and has served as Associate Editor of Therapeutic Advances in Gastroenterology, The Physician and Sports Medicine, Clinical Investigation, and has served as Assistant Editor-in-Chief of the World Journal of Gastroenterology. An invited lecturer at the local, national, and international levels, Dr. Lichtenstein is the author or coauthor of more than 325 peer-reviewed primary articles and chapters, and he has presented over 250 abstracts and edited 18 books. He has lectured at a national and an international level at over 500 invited conferences, lectures, symposiums and institutional grand rounds.
Millie D. Long, MD, MPH
Millie D. Long, MD, MPH
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
University of North Carolina
Chapel Hill, NC
Bio
Millie D. Long, MD, MPH, earned her doctor of medicine degree at the University of Virginia, where she was a Bowman Scholar. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina at Chapel Hill. While at University of North Carolina, she also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine and gastroenterology. Dr. Long is currently Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina. Her clinical practice is based at the University of North Carolina Inflammatory Bowel Diseases Center.
Dr. Long’s interests include research on prevention of complications of inflammatory bowel disease and women’s health. She is currently an investigator for the CCFA Partners cohort, a prospective cohort focusing upon patient reported outcomes that includes over 14,000 patients living with inflammatory bowel disease. Dr. Long has contributed numerous peer-reviewed publications, book chapters, and review articles to the medical literature. She currently serves as an invited reviewer for journals such as Inflammatory Bowel Diseases, Gastroenterology, and the American Journal of Gastroenterology. She is Associate Editor for the IBD section of the American Journal of Gastroenterology.
Dr. Long is a member of the American College of Gastroenterology, where she serves on the Research Committee; and a member of the American Gastroenterological Association, where she serves on the maintenance of certification committee. She is also a member of the Crohn’s and Colitis Foundation of America, where she chairs the Professional Education Committee.
Derek R. Patel, MD
Derek R. Patel, MD
Associate Clinical Services, Chief
Hillcrest Gastroenterology
San Diego, CA
Bio
Derek R. Patel, MD, earned his doctor of medicine degree at the University of California, Davis. He completed a residency at the University of California, San Francisco, in the Department of Medicine, and completed a gastroenterology fellowship at University of California, San Francisco, in the Division of Gastroenteroloy. Dr. Patel received additional training at the Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, in Los Angeles, California. He is board certified in internal medicine and gastroenterology. Dr. Patel is currently Associate Clinical Services, Chief, of Hillcrest Gastroenterology. He also participates in teaching activities through the University of California at San Diego’s School of Medicine.
Dr. Patel’s interests include research on inflammatory bowel disease, emergency department evaluation and management of patients with IBD, and other gastroenterological issues. Due to his research and expertise, Dr. Patel has participated in numerous presentations of which he was invited to speak. Dr. Patel has contributed numerous abstracts and publications to the medical literature, and has publishing worked in journals such as Clinical Gastroenterology Hepatology and Clinical Nephrology.
| 1. | Compare and contrast the clinical effects of the various IBD therapies | 2. | Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity |
| 3. | Utilize available disease progression and drug monitoring strategies for patients with IBD | 4. | Implement appropriate practice measures and quality of care process and outcomes measures in managing patients with IBD |
| 1. | Compare and contrast the clinical effects of the various IBD therapies |
| 2. | Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity |
| 3. | Utilize available disease progression and drug monitoring strategies for patients with IBD |
| 4. | Implement appropriate practice measures and quality of care process and outcomes measures in managing patients with IBD |
CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Crohn’s & Colitis Foundation of America, and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
The University of Cincinnati designates this enduring material activity for a maximum of 2.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
FACULTY DISCLOSURE DECLARATION
FACULTY DISCLOSURE DECLARATION
According to the disclosure policy of the University of Cincinnati, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
Disclosure will be made at the time of activity.
In accordance with the ACCME Standards for Commercial Support, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (e.g., paid speaker, employee, paid consultant on a board, and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made:
Sunanda Kane, MD, MSPH, discloses the following relationships with commercial interests:
- Advisory Board: 11 Health
- Consultant: AbbVie, Samsung
- Officer or Board Member: ACG, ABIM
- Grant Recipient: UCB
Sasha Taleban, MD, has no relevant relationships to disclose.
Gary R. Lichtenstein, MD, discloses the following relationships with commercial interests:
- Consultant: Abbott/AbbVie, Actavis, Alaven, Hospira, Luitpold/American Regent, Pfizer Pharmaceuticals, Romark, Takeda
- Consultant/Research: Celgene, Ferring, Janssen Biotech, Prometheus Laboratories, Receptos, Salix Pharmaceuticals/Valeant, Santarus, Shire Pharmaceuticals, UCB
- Speaker for CME activities: Ironwood, Luitpold/American Regent
- Editor (Honorarium): Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media
- Author (Honorarium): McMahon Publishing, Up-To-Date
- Book Royalty: SLACK, Inc.
Millie D. Long, MD, MPH, discloses the following relationships with commercial interests:
- Advisory Board: Abbvie, Pfizer, Takeda
- Consultant: AbbVie, Takeda, Theravance
- Research Support: Takeda
- Speaker for CME activities: AbbVie
Derek R. Patel, MD, discloses the following relationships with commercial interests:
- Speaker: AbbVie
- Advisory Board: AbbVie
The planners and managers reported the following financial relationships or relationships
to products or devices they or their spouse/life partner have with commercial interests
related to the content of this CME activity:
Crohn’s & Colitis Foundation of America
Orna Ehrlich, MPH, has no relevant relationships to disclose.
RMEI Medical Education, LLC
Sherri Kramer, MD, has no relevant relationships to disclose.
Kyra Sheahan has no relevant relationships to disclose.
Faith Reidenbach has no relevant relationships to disclose.
Nora Hartley has no relevant relationships to disclose.
University of Cincinnati
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, Director, has no relevant relationships to disclose.
Rick E. Ricer, MD, Professor Emeritus, has no relevant relationships to disclose.
Deborah Cole, BS, Program Coordinator, has no relevant relationships to disclose.
OFF-LABEL DISCLOSURE STATEMENT
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
LEARNER ASSURANCE STATEMENT
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
DISCLAIMER STATEMENT
The opinions expressed during the enduring material activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Estimated time to complete: 2.25 hours
Medium: Internet
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
This activity is supported by independent medical education grants from AbbVie, Celgene Corporation, Salix Pharmaceuticals, Takeda Pharmaceuticals U.S.A., Inc., and UCB, Inc.
HOW TO RECEIVE CREDIT
By completing the curriculum challenge (at the beginning and again at the end of the activity), the pre-test, reviewing the course content, and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 2.25 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page.
Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Contact Information:
Accreditation Support
Please contact the University of Cincinnati, Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.
Technical Support:
For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
